Ehsan Parvaresh Rizi
Research Subjects
Ehsan Parvaresh Rizi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Nowojewski
Clinical Pharmacology and Safety Sciences, Biopharmaceutical Research and Development, AstraZeneca, Cambridge, England, United Kingdom
2 shared publications - Anna Zarodkiewicz
Clinical Operations, Biopharmaceutical Research and Development, AstraZeneca, Warsaw, Poland
2 shared publications - Anneli Olsson
Division of Cardiology, Department of Clinical Sciences Lund Lund University Lund Sweden
2 shared publications - Annika Rutgersson
Evinova, AstraZeneca, Mölndal, Sweden
2 shared publications - Daniel A. Jones
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London
2 shared publications - David Austin
Academic Cardiovascular Unit, The James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, England, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e91299
Medication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study
Background: Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. Objective: This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. Methods: DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. Results: In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. Conclusions: This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models.
- 21 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e91299
Open AccessMedication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study
Background: Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. Objective: This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. Methods: DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. Results: In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. Conclusions: This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models.
- Open Access
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Medication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study (Preprint)
BACKGROUND Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. OBJECTIVE This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. METHODS DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. RESULTS In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. CONCLUSIONS This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models. CLINICALTRIAL
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMedication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study (Preprint)
BACKGROUND Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. OBJECTIVE This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. METHODS DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. RESULTS In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. CONCLUSIONS This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models. CLINICALTRIAL
- Open Access
- 1 November 2015
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (11) , 4249-4256
Ethnic Differences in the Role of Adipocytokines Linking Abdominal Adiposity and Insulin Sensitivity Among Asians
Among Asian ethnic groups, Chinese or Malays are more insulin sensitive than South- Asians, in particular in lean individuals.Wehave further reported that body fat partitioning did not explain this ethnic difference in insulin sensitivity. We examined whether adipocytokines might explain the ethnic differences in the relationship between obesity and insulin resistance among the three major ethnic groups in Singapore. This was a cross-sectional study. We studied 101 Chinese, 82 Malays, and 81 South-Asian men. Insulin sensitivity index (ISI) was measured using hyperinsulinemic euglycemic clamp. Visceral (VAT) and subcutaneous (SAT) adipose tissue volumes were quantified using magnetic resonance imaging. Plasma total and high-molecular-weight adiponectin, leptin, visfatin, apelin, interleukin-6 (IL-6), fibroblast growth factor 21 (FGF21), retinol binding protein-4 (RBP-4) and resistin were measured using enzyme linked immunoassays. Principle component analysis on the adipocytokines identified 3 principal components (PCs) which explained 49.5% of the total variance. Adiponectin loaded negatively, and leptin and FGF21 loaded positively onto PC1. Visfatin, resistin and apelin all loaded positively onto PC2. IL-6 loaded positively and RBP-4 negatively onto PC3. Only PC1 was negatively associated with ISI in all ethnic groups. In the path analysis, SAT and VAT were negatively associated with ISI in Chinese and Malays without significant mediatory role of PC1. In South-Asians, the relationship between VAT and ISI was mediated partly through PC1, whereas the relationship between SAT and ISI was mediated mainly through PC1. The relationships between abdominal obesity, adipocytokines and insulin sensitivity differ between ethnic groups. Adiponectin, leptin and FGF21 play a mediating role in the relationship between abdominal adiposity and insulin resistance in South-Asians, but not in Malays or Chinese.
- 1 November 2015
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (11) , 4249-4256
Open AccessEthnic Differences in the Role of Adipocytokines Linking Abdominal Adiposity and Insulin Sensitivity Among Asians
Among Asian ethnic groups, Chinese or Malays are more insulin sensitive than South- Asians, in particular in lean individuals.Wehave further reported that body fat partitioning did not explain this ethnic difference in insulin sensitivity. We examined whether adipocytokines might explain the ethnic differences in the relationship between obesity and insulin resistance among the three major ethnic groups in Singapore. This was a cross-sectional study. We studied 101 Chinese, 82 Malays, and 81 South-Asian men. Insulin sensitivity index (ISI) was measured using hyperinsulinemic euglycemic clamp. Visceral (VAT) and subcutaneous (SAT) adipose tissue volumes were quantified using magnetic resonance imaging. Plasma total and high-molecular-weight adiponectin, leptin, visfatin, apelin, interleukin-6 (IL-6), fibroblast growth factor 21 (FGF21), retinol binding protein-4 (RBP-4) and resistin were measured using enzyme linked immunoassays. Principle component analysis on the adipocytokines identified 3 principal components (PCs) which explained 49.5% of the total variance. Adiponectin loaded negatively, and leptin and FGF21 loaded positively onto PC1. Visfatin, resistin and apelin all loaded positively onto PC2. IL-6 loaded positively and RBP-4 negatively onto PC3. Only PC1 was negatively associated with ISI in all ethnic groups. In the path analysis, SAT and VAT were negatively associated with ISI in Chinese and Malays without significant mediatory role of PC1. In South-Asians, the relationship between VAT and ISI was mediated partly through PC1, whereas the relationship between SAT and ISI was mediated mainly through PC1. The relationships between abdominal obesity, adipocytokines and insulin sensitivity differ between ethnic groups. Adiponectin, leptin and FGF21 play a mediating role in the relationship between abdominal adiposity and insulin resistance in South-Asians, but not in Malays or Chinese.